CFDE Data Portal | Search SLEAR

	Label	Description
	SLEAR Gene (Entity type)	ENSG00000248599 - STAT1 regulated ILF2 complex interacting lncRNA
	GSE162892 ISOX 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119007 prostaglandin TS-A clone E2 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 nicotinamide 14 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 dasatinib 8 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE264632 GSE264730 IDH1 inhibition 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE130401 trametinib YAP 6 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

SLEAR

ENSG00000248599 - STAT1 regulated ILF2 complex interacting lncRNA

GSE162892 ISOX 3 v 0 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

GSE108464 AZ-628 1 v 2 human dn

A Gene Set from LINCS

GSE119007 prostaglandin TS-A clone E2 1 v 0 human dn

A Gene Set from LINCS

GSE233679 nicotinamide 14 v 15 human up

A Gene Set from LINCS

GSE239844 crizotinib 6 v 0 human up

A Gene Set from LINCS

GSE135514 dasatinib 8 v 9 human up

A Gene Set from LINCS

GSE264632 GSE264730 IDH1 inhibition 0 v 2 human dn

A Gene Set from LINCS

GSE130401 trametinib YAP 6 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.